Get startedLog in
    Picture of Cohance Lifesciences logo

    COHANCE — Cohance Lifesciences Cashflow Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareBalancedMid CapFalling Star
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Cohance Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    C2021
    March 31st
    2022
    March 31st
    C2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IAS
    IAS
    IAS
    IAS
    IAS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line4,6776,6765,5974,0573,439
    Depreciation
    Non-Cash Items52.623.8-90-365-177
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-1,216-3,782-1,400-625-1,156
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities3,8253,3004,5723,5852,882
    Capital Expenditures-1,108-752-2,859-518-1,557
    Purchase of Fixed Assets
    Other Investing Cash Flow Items-2,006-610909-3,105-996
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-3,114-1,362-1,950-3,623-2,553
    Financing Cash Flow Items-86.7-61.4-116-74.5-104
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-757-1,564-2,420-13833.2
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-45.1374202-176382